Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 17/20 | 0.71 |
| ▸ | KDM6B | O15054 | 2/20 | 0.65 |
| ▸ | KDM4D | Q6B0I6 | 2/20 | 0.65 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.65 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.55 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.55 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14349756 | 0.95 | HCAR2 (0.74) | HCAR2KDM6BKDM4DKDM4CEGLN3 | |
| SCHEMBL14349762 | 0.88 | HCAR2 (0.64) | HCAR2KDM6BKDM4DKDM4CEGLN3 | |
| SCHEMBL5623042 | 0.88 | HCAR2 (0.85) | HCAR2 | |
| SCHEMBL14349720 | 0.83 | HCAR2 (1.00) | HCAR2CYP2C9 | |
| SCHEMBL14349727 | 0.82 | HCAR2 (0.80) | HCAR2 | |
| SCHEMBL14349747 | 0.82 | HCAR2 (0.80) | HCAR2 | |
| SCHEMBL14349749 | 0.82 | HCAR2 (0.80) | HCAR2 | |
| SCHEMBL14349735 | 0.81 | HCAR2 (1.00) | HCAR2 | |
| SCHEMBL14349744 | 0.81 | HCAR2 (0.78) | HCAR2TRPV1 | |
| SCHEMBL14349748 | 0.81 | HCAR2 (0.78) | HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070299101-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME CORP. | 2007-12-27 | — | — | US | disclosed |
| US-20070299101-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME CORP. | 2007-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299101-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | LDLR, APOB, FFAR1 | HCAR2 20/4885KDM6B 4689/4885KDM4D 4754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.